Dr. Grey AI

Oritavancin (Orbactiv)

Peptide

Oritavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved August 2014. Single-dose therapy: 1200 mg IV infusion provides complete treatment. SOLO-1 & SOLO-2 Phase 3 (n=1987): Noninferior to 7-10 day vancomycin course (81.2% vs 80.9% composite endpoint). Superior MRSA lesion reduction (93.1% vs 87.1%, P=0.032). Half-life 245 hours enables once-only dosing. Coverage: MRSA, MSSA, Streptococci, E. faecalis. Vancomycin derivative with enhanced lipophilic properties.

Quick Answer

What it is

Oritavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved August 2014.

Key findings

  • Grade A: Clinical Cure Rate (Skin and Soft Tissue Infections)
  • Grade A: MRSA Efficacy (Skin and Soft Tissue Infections)
  • Grade A: Early Clinical Response (Skin and Soft Tissue Infections)

Safety

  • Pooled safety (n=1959): Adverse events 55.3% vs 56.9% vancomycin.
  • No renal toxicity advantage over vancomycin in ABSSSI.
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Oritavancin (Orbactiv)

Quick Facts: Oritavancin (Orbactiv)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:5
  • Grade A Findings:4
  • Key Effect:Skin and Soft Tissue Infections
A4
B0
C1
D0
1 conditions · 5 outcomes

Detailed Outcomes

A
Clinical Cure Rate
SOLO-1 & SOLO-2 pooled (n=1987): Primary composite endpoint 81.2% oritavancin vs 80.9% vancomycin (noninferior). Investigator-assessed clinical cure 81.2% vs 80.2%. Single dose noninferior to 7-10 day vancomycin. NCT01252719, NCT01252732.
none
A
MRSA Efficacy
SOLO trials (n=405 MRSA): ≥20% lesion size reduction 93.1% oritavancin vs 87.1% vancomycin (difference 6.1%, P=0.032). Statistically superior to vancomycin for MRSA infections specifically.
small↑Improves
A
Early Clinical Response
≥20% lesion area reduction at 48-72h: 86.4% oritavancin vs 84.1% vancomycin. Met FDA-required early clinical response endpoint. Enables outpatient treatment with single hospital visit.
none
A
Safety Profile
Pooled safety (n=1959): Adverse events 55.3% vs 56.9% vancomycin. Serious AEs 5.8% vs 5.9%. Common: nausea, headache, vomiting. Infusion-related reactions ~3%. No renal toxicity advantage over vancomycin in ABSSSI.
none
C
Antimicrobial Activity
26 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
moderate↑Improves

Research Citations (33)

Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review.
(2025)
PMID: 40872608
A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?
(2025)
PMID: 40903703
Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies.
(2025)
PMID: 41224240
Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes.
(2024)
PMID: 39493938
Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments.
(2023)
PMID: 37109488
The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.
(2023)
PMID: 37887199
The role of long-acting antibiotics in the clinical practice: a narrative review.
(2023)
PMID: 38075413
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.
(2022)
PMID: 35392455
Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis.
(2021)
PMID: 33989846
Glycopeptide Hypersensitivity and Adverse Reactions.
(2020)
PMID: 32326261

Related Peptides

Telavancin (Vibativ)

Peptide

1 shared condition · 7 outcomes

Telavancin is a semi-synthetic lipoglycopeptide antibiotic with dual mechanism of action. FDA-approved September 2009 (cSSSI) and June 2013 (HABP/VABP). ATLAS trials (n=1794): Clinical cure 88.3% vs 87.1% vancomycin (noninferior) for cSSSI. ATTAIN trials: Approved for hospital-acquired pneumonia when alternatives not suitable. Coverage: MRSA, MSSA, Streptococci, E. faecalis. SAFETY CONCERN: Higher mortality in patients with pre-existing renal impairment; use when alternatives not suitable.

Daptomycin (Cubicin)

Peptide

1 shared condition · 12 outcomes

Daptomycin is a cyclic lipopeptide antibiotic for serious gram-positive infections. FDA-approved 2003 (cSSSI) and 2006 (S. aureus bacteremia/endocarditis). First-in-class lipopeptide with rapid bactericidal activity against MRSA/MSSA. Phase 3: cSSSI success 83.4% vs 84.2% comparators (n=902). Bacteremia/endocarditis: 44.2% vs 41.7% standard therapy (noninferior, P met). Significantly less nephrotoxicity than vancomycin+gentamicin (11.0% vs 26.3%, P=0.004). SAFETY CONCERN: CPK elevation/myopathy (2.8%), monitor weekly; eosinophilic pneumonia (rare but serious); avoid with statins.

Dalbavancin (Dalvance)

Peptide

1 shared condition · 6 outcomes

Dalbavancin is a second-generation lipoglycopeptide antibiotic for acute bacterial skin infections. FDA-approved May 2014. Once-weekly or single-dose therapy: 1500 mg single dose OR 1000 mg + 500 mg at 1 week. DISCOVER-1 & DISCOVER-2 Phase 3: Noninferior to vancomycin/linezolid 14-day course (79.7% vs 79.8%). Half-life >1 week enables weekly dosing. Coverage: MRSA (MIC <0.125 µg/mL), MSSA, Streptococci. Pediatric approval 2021 (birth and older). First single-dose complete ABSSSI treatment.